What is Needham's price target for KALV?

Needham's latest stated price target for KalVista Pharmaceuticals Inc. (KALV) is $35, from its action on Jan 9, 2026.

What is Needham's rating on KALV?

Needham rates KALV Buy, a bullish rating, as of Jan 9, 2026.

When did Needham last change its view on KALV?

On Jan 9, 2026, Needham raises its price target to $35 from $32, keeps Buy.

Needham KALV price target and rating history

KalVista Pharmaceuticals Inc. (KALV) · Health Care

Needham rates KalVista Pharmaceuticals Inc. (KALV) Buy with a $35 price target, as of its latest action on Jan 9, 2026. It has published 4 rating actions on KALV since December 2021, including 0 upgrades and 0 downgrades.

Current rating: Buy
Price target: $35
Median target, all firms: Too few
Actions on KALV: 4

Needham price target on KALV

Needham price target on KALV, each point a stated target, December 2021 to January 2026.

Every Needham rating on KALV

Jan 9, 2026
ReiterateNeedham raises its price target to $35 from $32, keeps Buy
Jan 6, 2026
ReiterateNeedham raises its price target to $32 from $28, keeps Buy
Mar 11, 2022
ReiterateNeedham cuts its price target to $42 from $48, keeps Buy
Dec 10, 2021
ReiterateNeedham cuts its price target to $48 from $50, keeps Buy

How other firms rate KALV

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
H.C. Wainwright	Neutral	$27	May 1, 2026
Needham	Buy	$35	Jan 9, 2026

Questions about Needham and KALV

What is Needham's price target for KALV?: Needham's latest stated price target for KalVista Pharmaceuticals Inc. (KALV) is $35, from its action on Jan 9, 2026.
What is Needham's rating on KALV?: Needham rates KALV Buy, a bullish rating, as of Jan 9, 2026.
When did Needham last change its view on KALV?: On Jan 9, 2026, Needham raises its price target to $35 from $32, keeps Buy.

All Needham ratings KALV news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.